Published in Acta Neurol Scand on March 01, 2001
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One (2011) 1.74
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med (2010) 1.24
GM-CSF action in the CNS decreases food intake and body weight. J Clin Invest (2005) 1.23
Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation (2005) 1.16
The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One (2009) 1.15
GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia. J Neuroinflammation (2012) 1.04
Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry (2010) 1.03
Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Hum Mol Genet (2009) 1.01
Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res Ther (2009) 1.00
Expression of glia maturation factor in neuropathological lesions of Alzheimer's disease. Neuropathol Appl Neurobiol (2012) 0.98
Differential ex vivo nitric oxide production by acutely isolated neonatal and adult microglia. J Neuroimmunol (2007) 0.92
An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin. Proc Natl Acad Sci U S A (2006) 0.92
Augmented expression of glia maturation factor in Alzheimer's disease. Neuroscience (2011) 0.91
Differential effects of duration and age on the consequences of neuroinflammation in the hippocampus. Neurobiol Aging (2013) 0.88
Cilostazol prevents amyloid β peptide(25-35)-induced memory impairment and oxidative stress in mice. Br J Pharmacol (2010) 0.87
miR-155 is involved in Alzheimer's disease by regulating T lymphocyte function. Front Aging Neurosci (2015) 0.86
Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer's disease and multiple sclerosis. J Neurochem (2009) 0.82
Early-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics (2015) 0.79
The Postprandial Effects of a Moderately High-Fat Meal on Lipid Profiles and Vascular Inflammation in Alzheimer's Disease Patients: A Pilot Study. J Gen Pract (Los Angel) (2015) 0.77
Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab (2016) 0.76
Intracerebral GM-CSF contributes to transendothelial monocyte migration in APP/PS1 Alzheimer's disease mice. J Cereb Blood Flow Metab (2016) 0.75
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods (1983) 6.71
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med (2001) 5.06
The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model. Infect Immun (1993) 4.00
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol (1995) 3.23
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Histopathological and serological progression of experimental Staphylococcus aureus arthritis. Infect Immun (1992) 2.64
Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl (2000) 2.56
The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect Immun (1994) 2.44
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Experimental Staphylococcus aureus arthritis in mice. Infect Immun (1991) 2.24
Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res (2001) 2.19
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun (1997) 2.08
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Incidence of ROP in two consecutive Swedish population based studies. Br J Ophthalmol (2002) 1.86
CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand (2007) 1.85
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun (1997) 1.80
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand (1991) 1.77
Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum (1990) 1.75
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol (1999) 1.68
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect Immun (2000) 1.65
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol (2009) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med (1999) 1.61
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry (2003) 1.58
Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke (1995) 1.58
Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. Eur Respir J (2005) 1.56
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis. Infect Immun (1999) 1.52
Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol (1997) 1.51
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology (2004) 1.47
Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand (1994) 1.44
White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology (2010) 1.44
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure. Eur Respir J (2005) 1.39
Cerebrospinal fluid monoamine metabolites and atmospheric pressure. Biol Psychiatry (1996) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.38
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology (2006) 1.37
A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand (1987) 1.36
Genistein as an anti-inflammatory agent. Inflamm Res (2003) 1.35
Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest (1998) 1.35
Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci U S A (1994) 1.33
APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology (2004) 1.33
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett (1999) 1.32
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 1.32
Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci. Eur J Immunol (1994) 1.32
White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry (2007) 1.31
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun (2001) 1.30
The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology (1998) 1.30
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry (2005) 1.30
Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand (1990) 1.29
Mice with the xid B cell defect are less susceptible to developing Staphylococcus aureus-induced arthritis. J Immunol (1995) 1.28
CT evaluation of coverage and congruency of the hip prior to osteotomy. Clin Orthop Relat Res (1988) 1.28
Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study. J Neurol Neurosurg Psychiatry (2009) 1.28
Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Arthritis Rheum (1996) 1.27
Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. J Immunol (1995) 1.26
Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clin Exp Immunol (1990) 1.26
Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 1.26
Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus (2000) 1.26
A demineralization procedure for immunohistopathological use. EDTA treatment preserves lymphoid cell surface antigens. J Immunol Methods (1986) 1.25
White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol (1998) 1.25
Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J Immunol Methods (1984) 1.21
Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol (1998) 1.21
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) (2000) 1.20
Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci (2005) 1.20